AP2002002586A0 - Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors. - Google Patents

Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors.

Info

Publication number
AP2002002586A0
AP2002002586A0 APAP/P/2002/002586A AP2002002586A AP2002002586A0 AP 2002002586 A0 AP2002002586 A0 AP 2002002586A0 AP 2002002586 A AP2002002586 A AP 2002002586A AP 2002002586 A0 AP2002002586 A0 AP 2002002586A0
Authority
AP
ARIPO
Prior art keywords
substituted lower
compounds
nr9r10
pyrido
pyrimidine
Prior art date
Application number
APAP/P/2002/002586A
Other languages
English (en)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Vara Prasad Venkata Negendra Josyula
Dennis Joseph Mcnamara
Peter Laurence Toogood
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AP2002002586A0 publication Critical patent/AP2002002586A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
APAP/P/2002/002586A 2000-01-25 2001-01-23 Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors. AP2002002586A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25
PCT/IB2001/000069 WO2001055147A1 (en) 2000-01-25 2001-01-23 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
AP2002002586A0 true AP2002002586A0 (en) 2002-09-30

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2002/002586A AP2002002586A0 (en) 2000-01-25 2001-01-23 Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors.

Country Status (34)

Country Link
EP (1) EP1254137A1 (cs)
JP (1) JP4047010B2 (cs)
KR (1) KR20020065939A (cs)
CN (1) CN1395578A (cs)
AP (1) AP2002002586A0 (cs)
AR (1) AR030044A1 (cs)
AU (1) AU2542501A (cs)
BG (1) BG106850A (cs)
BR (1) BR0107751A (cs)
CA (1) CA2397961C (cs)
CO (1) CO5261549A1 (cs)
CR (1) CR6706A (cs)
CZ (1) CZ20022475A3 (cs)
DZ (1) DZ3266A1 (cs)
EA (1) EA200200643A1 (cs)
EE (1) EE200200405A (cs)
GT (1) GT200100016A (cs)
HN (1) HN2001000013A (cs)
HU (1) HUP0204141A3 (cs)
IL (1) IL150545A0 (cs)
IS (1) IS6443A (cs)
MA (1) MA26868A1 (cs)
MX (1) MXPA02007221A (cs)
NO (1) NO20023527L (cs)
OA (1) OA12161A (cs)
PA (1) PA8510701A1 (cs)
PE (1) PE20011066A1 (cs)
PL (1) PL356802A1 (cs)
SK (1) SK10632002A3 (cs)
SV (1) SV2002000294A (cs)
TN (1) TNSN01014A1 (cs)
WO (1) WO2001055147A1 (cs)
YU (1) YU50402A (cs)
ZA (1) ZA200205879B (cs)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN100525768C (zh) 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
KR20040103972A (ko) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
CA2579406A1 (en) * 2004-09-21 2006-03-30 F.Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
US7423042B2 (en) 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
ES2336603T3 (es) * 2005-07-21 2010-04-14 F. Hoffmann-La Roche Ag Compuestos de pirido(2,3-d)pirimidina-2,4-diamina como inhibidores de ptp1b.
WO2007021795A2 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CN102216299B (zh) * 2008-12-01 2015-02-11 默克专利有限公司 作为自体毒素抑制剂的2,5-二氨基取代的吡啶并[4,3-d]嘧啶化合物
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
US9815847B2 (en) 2013-03-14 2017-11-14 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
PL181893B1 (pl) * 1994-11-14 2001-10-31 Warner Lambert Co Zwiazki bedace pochodnymi pirymidyny i naftyrydyny oraz preparat farmaceutyczny zawierajacy je PL PL PL
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
TR200003429T2 (tr) * 1998-05-26 2001-07-23 Warner-Lambert Company Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.

Also Published As

Publication number Publication date
SK10632002A3 (sk) 2003-06-03
HUP0204141A2 (hu) 2003-04-28
SV2002000294A (es) 2002-07-16
GT200100016A (es) 2001-10-19
EA200200643A1 (ru) 2002-12-26
ZA200205879B (en) 2003-09-29
PL356802A1 (en) 2004-07-12
KR20020065939A (ko) 2002-08-14
IL150545A0 (en) 2003-02-12
EP1254137A1 (en) 2002-11-06
OA12161A (en) 2006-05-08
NO20023527D0 (no) 2002-07-24
AU2542501A (en) 2001-08-07
BR0107751A (pt) 2002-11-12
DZ3266A1 (fr) 2001-08-02
CA2397961C (en) 2008-08-26
CA2397961A1 (en) 2001-08-02
CR6706A (es) 2005-04-04
HN2001000013A (es) 2001-06-18
HUP0204141A3 (en) 2005-03-29
WO2001055147A1 (en) 2001-08-02
JP2003523357A (ja) 2003-08-05
NO20023527L (no) 2002-09-10
AR030044A1 (es) 2003-08-13
MA26868A1 (fr) 2004-12-20
YU50402A (sh) 2005-11-28
PE20011066A1 (es) 2001-10-22
CZ20022475A3 (cs) 2003-03-12
IS6443A (is) 2002-06-25
CN1395578A (zh) 2003-02-05
JP4047010B2 (ja) 2008-02-13
CO5261549A1 (es) 2003-03-31
TNSN01014A1 (fr) 2005-11-10
PA8510701A1 (es) 2002-12-11
EE200200405A (et) 2003-12-15
MXPA02007221A (es) 2002-11-29
BG106850A (bg) 2003-02-28

Similar Documents

Publication Publication Date Title
AP2002002586A0 (en) Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors.
BG106594A (en) Pteridinones as kinase inhibitors
RU2441869C2 (ru) Противовирусные соединения
AP2000001964A0 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
NZ627709A (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
RU2005127052A (ru) Соединения тиенопиримидина и их применение
GEP20063915B (en) PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
HRP20120351T1 (hr) Macrociklički derivati kinazolina kao antiproliferativna sredstva
TW221434B (cs)
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
IL150883A0 (en) Pyrimidine compounds
BRPI0517461A (pt) compostos farmacêuticos
AR006906A1 (es) Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis
TR199900481T2 (xx) �ndazol t�revleri; fosfodiesteraz tip IV inhibit�rleri olarak kullan�mlar�.
EP1233950A4 (en) 3,4-DIHYDRO (1H) CHINAZOLIN 2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS
CA2997039A1 (en) 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof
CN117751104A (zh) 一类具有激酶抑制功能的化合物及其制备和应用
DK0888356T3 (da) Kondenserede 2,3-benzodiazepinderivater og deres anvendelse som AMPA-receptohaemmere
AR027035A1 (es) Pirroles sustituidos
WO2002030932A3 (en) N8,n13-disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents
TH53887A (th) ไพริโด (2,3-d) , ไพริมิดีน-2.7- ไดเอมีนที่เป็นสารยับยั้งคิเนส
PE20020513A1 (es) COMPUESTOS DE 2,4,8-TRISUSTITUIDA-8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA